Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use.

Antibiotics (Basel)

Clinical Chemistry Laboratory, University of Milano-Bicocca, Azienda Socio Sanitaria Territoriale di Monza ASST-Monza, San Gerardo Hospital, Via Pergolesi 33, 20900 Monza, Italy.

Published: August 2021

The β-lactams have a central place in the antibacterial armamentarium, but the increasing resistance to these drugs, especially among Gram-negative bacteria, is becoming one of the major threats to public health worldwide. Treatment options are limited, and only a small number of novel antibiotics are in development. However, one of the responses to this threat is the combination of β-lactam antibiotics with β-lactamase inhibitors, which are successfully used in the clinic for overcoming resistance by inhibiting β-lactamases. The existing inhibitors inactivate most of class A and C serine β-lactamases, but several of class D and B (metallo-β-lactamase) are resistant. The present review provides the status and knowledge concerning current β-lactamase inhibitors and an update on research efforts to identify and develop new and more efficient β-lactamase inhibitors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388860PMC
http://dx.doi.org/10.3390/antibiotics10080995DOI Listing

Publication Analysis

Top Keywords

β-lactamase inhibitors
12
beta-lactamase inhibitors
4
inhibitors molecular
4
molecular structure
4
structure mechanism
4
mechanism action
4
action clinical
4
clinical β-lactams
4
β-lactams central
4
central place
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!